Public Employees Retirement System of Ohio Has $1.81 Million Position in Omnicell, Inc. $OMCL

Public Employees Retirement System of Ohio boosted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 6,712.8% in the first quarter, Holdings Channel reports. The firm owned 54,298 shares of the company’s stock after acquiring an additional 53,501 shares during the period. Public Employees Retirement System of Ohio’s holdings in Omnicell were worth $1,812,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 6.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after buying an additional 137,834 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Omnicell by 156.4% during the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after buying an additional 1,265,818 shares during the period. Lazard Asset Management LLC grew its stake in Omnicell by 3.8% in the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Omnicell by 2.0% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after buying an additional 27,497 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Omnicell by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after acquiring an additional 11,424 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Insider Transactions at Omnicell

In other news, EVP Corey J. Manley sold 5,025 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president directly owned 112,783 shares of the company’s stock, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

OMCL has been the subject of a number of research analyst reports. Weiss Ratings raised shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Wells Fargo & Company lowered their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. KeyCorp cut their price objective on Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Craig Hallum restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $58.43.

Trending Headlines about Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported second-quarter adjusted EPS of $0.94, well above the $0.47–$0.48 consensus, while revenue rose 7.4% year over year to $312.2 million and also exceeded estimates. GAAP net income increased to $24 million from $6 million a year earlier. Omnicell Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year 2026 non-GAAP EPS outlook to $2.15–$2.30, above the roughly $1.81 analyst consensus, and lifted its full-year revenue outlook to $1.225–$1.245 billion. Demand for connected devices, technical services and SaaS offerings, along with cost controls and tariff refunds, supported results. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted
• Positive Sentiment: Omnicell highlighted momentum in its Titan XT and OmniSphere platforms, pointing to pipeline growth and longer-term opportunities in medication-management automation. KeyCorp maintained an “overweight” rating, although it reduced its price target from $70 to $65. OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Omnicell Stock Performance

OMCL opened at $35.37 on Friday. The stock has a market cap of $1.61 billion, a PE ratio of 42.11, a P/E/G ratio of 0.92 and a beta of 0.96. The company has a current ratio of 1.64, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 1 year low of $28.90 and a 1 year high of $55.00. The stock’s 50 day simple moving average is $41.97 and its 200-day simple moving average is $41.09.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same period last year, the business earned $0.45 earnings per share. Omnicell’s quarterly revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Sell-side analysts forecast that Omnicell, Inc. will post 1.31 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.